Treatment Patterns and Health Outcomes Among Patients with Radioiodine-Refractory Differentiated Thyroid Cancer in the United States and Western Europe.

Gianoukakis, A G; Flores, N M; Pelletier, C L; DiBonaventura, M; Forsythe, A; Wolfe, G; Rege, J; Taylor, M H

Gianoukakis, A G; Flores, N M; Pelletier, C L; DiBonaventura, M; Forsythe, A; Wolfe, G; Rege, J; Taylor, M H.

Afiliação

Gianoukakis AG; University of California, Los Angeles, Torrance, CA, USA.
Flores NM; Kantar Health, New York, NY, USA.
Pelletier CL; Eisai Inc, Woodcliff Lake, NJ, USA.
DiBonaventura M; Kantar Health, New York, NY, USA.
Forsythe A; Eisai Inc, Woodcliff Lake, NJ, USA.
Wolfe G; Kantar Health, New York, NY, USA.
Rege J; Eisai Inc, Woodcliff Lake, NJ, USA.
Taylor MH; Oregon Health & Science University, Division of Hematology & Medical Oncology, Portland, OR, USA.

Value Health ; 17(7): A614, 2014 Nov.

Article em En | MEDLINE | ID: mdl-27202148

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2014 Tipo de documento: Article